

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (canceled).
2. (previously presented) A human monoclonal antibody that binds to Platelet Derived Growth Factor D (PDGFD) and comprises a heavy chain amino acid sequence comprising SEQ ID NO: 48 and a light chain amino acid sequence comprising SEQ ID NO: 49.
- 3-22. (canceled)
23. (previously presented) A human monoclonal antibody or antigen-binding portion thereof that specifically binds to Platelet Derived Growth Factor D (PDGFD) and is encoded by human V<sub>H</sub>1-8 gene and J<sub>H</sub>6B gene, wherein said monoclonal antibody comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO:48 and a light chain polypeptide comprising the sequence of SEQ ID NO:49.
- 24-32. (canceled)
33. (previously presented) A human monoclonal antibody that binds to Platelet Derived Growth Factor D (PDGFD) and is derived from V<sub>H</sub>1-8 and J<sub>H</sub>6B, wherein said monoclonal antibody comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO:48 and a light chain polypeptide comprising the sequence of SEQ ID NO:49.
- 34-43.(canceled)
44. (previously presented) A composition comprising a human monoclonal antibody or antigen-binding portion thereof that specifically binds to Platelet Derived Growth Factor D (PDGFD) and is encoded by human V<sub>H</sub>1-8 gene and J<sub>H</sub>6B gene, wherein said human monoclonal antibody or antigen-binding portion thereof comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO:48 and a light chain polypeptide comprising the sequence of SEQ ID NO:49 in association with a pharmaceutically acceptable carrier.
45. (canceled)